Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5536-5545

  Chen, Huifen ^a   Chan, Bryan K ^a   Drummond, Jason ^a   Estrada, Anthony A ^a   Gunzner Toste, Janet ^a   Liu, Xingrong ^a   Liu, Yichin ^a   Moffat, John ^a   Shore, Daniel ^a   Sweeney, Zachary K ^a,b   Tran, Thuy ^a   Wang, Shumei ^a   Zhao, Guiling ^a   Zhu, Haitao ^a   Burdick, Daniel J ^a  

^a GENENTECH INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HYDROPHILICITY; MOLECULAR MODEL; PARKINSON DISEASE; PROCESS OPTIMIZATION; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BRAIN; COMPUTATIONAL BIOLOGY; HUMANS; JANUS KINASE 2; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MORPHOLINES; PERMEABILITY; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; PYRIMIDINES; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84862274036     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300452p     Document Type: Article

References (64)

1. Lees, A. J.; Hardy, J.; Revesz, T. Parkinson's disease Lancet 2009, 373, 2055-2066
2. Erratum in Lancet 2009, 374, 684.
3. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; Stoessl, A. J.; Pfeiffer, R. F.; Patenge, N.; Carbajal, I. C.; Vieregge, P.; Asmus, F.; Muller-Myhsok, B.; Dickson, D. W.; Meitinger, T.; Strom, T. M.; Wszolek, Z. K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 2004, 44, 601-607
4. Paisan-Ruiz, C.; Jain, S.; Evans, E. W.; Gilks, W. P.; Simon, J.; van der Brug, M.; Lopez de Munain, A.; Aparicio, S.; Gil, A. M.; Khan, N.; Johnson, J.; Martinez, J. R.; Nicholl, D.; Carrera, I. M.; Pena, A. S.; de Silva, R.; Lees, A.; Marti-Masso, J. F.; Perez-Tur, J.; Wood, N. W.; Singleton, A. B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 2004, 44, 595-600
5. Dachsel, J. C.; Farrer, M. J. LRRK2 and Parkinson disease Arch. Neurol. 2010, 67, 542-547
6. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A.; Tomiyama, H.; Nakashima, K.; Hasegawa, K.; Obata, F.; Yoshikawa, T.; Kawakami, H.; Sakoda, S.; Yamamoto, M.; Hattori, N.; Murata, M.; Nakamura, Y.; Toda, T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease Nat. Genet. 2009, 41, 1303-1307
7. Simón-Sánchez, J.; Schulte, C.; Bras, J. M.; Sharma, M.; Gibbs, J. R.; Berg, D.; Paisan-Ruiz, C.; Lichtner, P.; Scholz, S. W.; Hernandez, D. G.; Krüger, R.; Federoff, M.; Klein, C.; Goate, A.; Perlmutter, J.; Bonin, M.; Nalls, M. A.; Illig, T.; Gieger, C.; Houlden, H.; Steffens, M.; Okun, M. S.; Racette, B. A.; Cookson, M. R.; Foote, K. D.; Fernandez, H. H.; Traynor, B. J.; Schreiber, S.; Arepalli, S.; Zonozi, R.; Gwinn, K.; van der Brug, M.; Lopez, G.; Chanock, S. J.; Schatzkin, A.; Park, Y.; Hollenbeck, A.; Gao, J.; Huang, X.; Wood, N. W.; Lorenz, D.; Deuschl, G.; Chen, H.; Riess, O.; Hardy, J. A.; Singleton, A. B.; Gasser, T. Genome-wide association study reveals genetic risk underlying Parkinson's disease Nat. Genet. 2009, 41, 1308-1312
8. Mata, I. F.; Wedemeyer, W. J.; Farrer, M. J.; Taylor, J. P.; Gallo, K. A. LRRK2 in Parkinson's disease: protein domains and functional insights Trends Neurosci. 2006, 29, 286-293
9. Greggio, E.; Cookson, M. R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions ASN Neuro 2009, 1 (e00002) 13-24
10. Gandhi, P. N.; Chen, S. G.; Wilson-Delfosse, A. L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease J. Neurosci. Res. 2009, 87, 1283-1295
11. Drolet, R. E.; Sanders, J. M.; Kern, J. T. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions J. Neurogenet. 2011, 25, 140-151
12. West, A. B.; Moore, D. J.; Biskup, S.; Bugayenko, A.; Smith, W. W.; Ross, C. A.; Dawson, V. L.; Dawson, T. M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 16842-16847
13. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M. P.; Beilina, A.; Blackinton, J.; Thomas, K. J.; Ahmad, R.; Miller, D. W.; Kesavapany, S.; Singleton, A.; Lees, A.; Harvey, R. J.; Harvey, K.; Cookson, M. R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin Neurobiol. Dis. 2006, 23, 329-341
14. Cookson, M. R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease Nat. Rev. Neurosci. 2010, 11, 791-797
15. Rudenko, I. N.; Chia, R.; Cookson, M. R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med. 2012, 10, 20-27
16. Liu, Z.; Hamamichi, S.; Lee, B. D.; Yang, D.; Ray, A.; Caldwell, G. A.; Caldwell, K. A.; Dawson, T. M.; Smith, W. W.; Dawson, V. L. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models Hum. Mol. Genet. 2011, 20, 3933-3942
17. Lee, B. D.; Shin, J.-H.; VanKampen, J.; Petrucelli, L.; West, A. B.; Ko, H. S.; Lee, Y.-I.; Maguire-Zeiss, K. A.; Bowers, W. J.; Federoff, H. J.; Dawson, V. L.; Dawson, T. M. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease Nat. Med. 2010, 16, 998-1000
18. Garcia-Serna, R.; Mestres, J. Chemical Probes for biological systems Drug Discovery Today 2011, 16, 99-106
19. Deng, X.; Dzamko, N.; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J.-D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 2011, 7, 203-205
20. Ramsden, N.; Perrin, J.; Ren., Z.; Lee, B. D.; Zinn, N.; Dawson, V. L.; Tam, D.; Bova, M.; Lang, M.; Drewes, G.; Bantscheff, M.; Bard, F.; Dawson, T. M.; Hopf, C. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem. Biol. 2011, 6, 1021-1028
21. Zhang, J.; Deng, X.; Choi, H. G.; Alessi, D. R.; Gray, N. S. Characterization of TAE684 as a potent LRRK2 kinase inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 1864-1869
22. Kramer, T.; Lo Monte, F.; Goering, S.; Okala Amombo, G. M.; Schmidt, B. Small molecule kinase inhibitors for LRRK2 and their application to parkinson's disease models ACS Chem. Neurosci. 2012, 3, 151-160
23. Lovitt, B; Vanderporten, E. C.; Sheng, Z.; Zhu, H.; Drummond, J.; Liu, Y. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2) Biochemistry 2010, 49, 3092-3100
24. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
25. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
26. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
27. Moore, W. J.; Richard, D.; Thorarensen, A. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola Expert Opin. Ther. Pat. 2010, 20, 1703-1722
28. Deng, J.; Lewis, P. A.; Greggio, E.; Sluch, E.; Beilina, A.; Cookson, M. R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1499-1504
29. Marín, I. The Parkinson disease gene LRRK2: evolutionary and structural insights Mol. Biol. Evol. 2006, 23, 2423-2433
30. Nichols, R. J.; Dzamko, N.; Hutti, J. E.; Cantley, L. C.; Deak, M.; Moran, J.; Bamborough, P.; Reith, A. D.; Alessi, D. R. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease Biochem. J. 2009, 424, 47-60
31. Liu, M.; Kang, S.; Ray, S.; Jackson, J.; Zaitsev, A. D.; Gerber, S. A.; Cuny, G. D.; Glicksman, M. A. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant Biochemistry 2011, 50, 9399-9408
32. Cavasotto, C. N.; Phatak, S. S. Homology modeling in drug discovery: current trends and applications Drug Discovery Today 2009, 14, 676-683
33. Grant, M. A. Protein structure prediction in structure-based ligand design and virtual screening Comb. Chem. High Throughput Screening 2009, 12, 940-960
34. Cavasotto, C. N. Homology models in docking and high-throughput docking Curr. Top. Med. Chem. 2011, 11, 1528-1534
35. Bairoch, A.; Boeckmann, B.; Ferro, S.; Gasteiger, E. Swiss-Prot: juggling between evolution and stability Briefings Bioinf. 2004, 5, 39-55
36. Altschul, S. F.; Madden, T. L.; Schäffer, A. A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Nucleic Acids Res. 1997, 25, 3389-3402
37. MOE, version 2009.10; Chemical Computing Group Inc.: Montreal, Canada.
38. Wang, T.; Duffy, J. P.; Wang, J.; Halas, S.; Salituro, F. G.; Pierce, A. C.; Zuccola, H. J.; Black, J. R.; Hogan, J. K.; Jepson, S.; Shlyakter, D.; Mahajan, S.; Gu, Y.; Hoock, T.; Wood, M.; Furey, B. F.; Frantz, J. D.; Dauffenbach, L. M.; Germann, U. A.; Fan, B.; Namchuk, M.; Bennani, Y. L.; Ledeboer, M. W. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole J. Med. Chem. 2009, 52, 7938-7941
39. Covy, J. P.; Giasson, B. I. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2 Biochem. Biophys. Res. Commun. 2009, 378, 473-477
40. Maestro; Schrödinger, Inc.: New York, 2009.
41. Gould, C.; Wong, C. F. Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis Pharmacol. Ther. 2002, 93, 169-178
42. Caffrey, D. R.; Lunney, E. A.; Moshinsky, D. J. Prediction of specificity-determining residues for small-molecule kinase inhibitors BMC Bioinf. 2008, 9, 491-505
43. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics 2010, 26, 198-204
44. Posy, S. L.; Hermsmeier, M. A.; Vaccaro, W.; Ott, K. H.; Todderud, G.; Lippy, J. S.; Trainor, G. L.; Loughney, D. A.; Johnson, S. R. Trends in kinase selectivity: insights for target class-focused library screening J. Med. Chem. 2011, 54, 54-66
45. Martin, E.; Mukherjee, P.; Sullivan, D.; Jansen, J. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity J. Chem. Inf. Model. 2011, 51, 1942-1956
46. Anderson, P. C; De Sapio, V.; Turner, K. B.; Elmer, S. P.; Roe, D. C.; Schoeniger, J. S. Identification of binding specificity-determining features in protein families J. Med. Chem. 2012, 55, 1926-1939
47. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934
48. Korr, D.; Toschi, L.; Donner, P.; Pohlenz, H. D.; Kreft, B.; Weiss, B. LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain Cell. Signalling 2006, 18, 910-920
49. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275
50. Erratum in Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 2025.
51. Anderson, D. R.; Meyers, M. J.; Vernier, W. F.; Mahoney, M. W.; Kurumbail, R. G.; Caspers, N.; Poda, G. I.; Schindler, J. F.; Reitz, D. B.; Mourey, R. J. Pyrrolopyridine inhibitors of mitogen-activated protein kinase activated protein kinase 2 (MK-2) J. Med. Chem. 2007, 50, 2647-2654
52. Huggins, D. J.; Sherman, W.; Tidor, B. Rational approaches to improving selectivity in drug design J. Med. Chem. 2012, 55, 1424-1444
53. Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; Kenny, P. W.; Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure J. Med. Chem. 2006, 49, 6672-6682
54. Peltason, L.; Bajorath, J. SAR index: quantifying the nature of structure-activity relationships J. Med. Chem. 2007, 50, 5571-5578
55. Wassermann, A. M.; Bajorath, J. Chemical substitutions that introduce activity cliffs across different compound classes and biological targets J. Chem. Inf. Model. 2010, 50, 1248-1256
56. Peltason, L.; Bajorath, J. Computational analysis of activity and selectivity cliffs Methods Mol. Biol. 2011, 672, 119-132
57. Griffen, E.; Leach, A. G.; Robb, G. R.; Warner, D. J. Matched molecular pairs as a medicinal chemistry tool J. Med. Chem. 2011, 54, 7739-7750
58. Seebeck, B.; Wagener, M.; Rarey, M. From activity cliffs to target-specific scoring models and pharmacophore hypotheses ChemMedChem 2011, 6, 1630-1639
59. Scherrmann, J. M. Expression and function of multidrug resistance transporters at the blood-brain barriers Expert Opin. Drug Metab. Toxicol. 2005, 1, 233-246
60. Schinkel, A. H. P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv. Drug Delivery Rev. 1999, 36, 179-194
61. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074
62. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice Nucleic Acids Res. 1994, 22, 4673-4680
63. Pipeline Pilot, version 7.5; Accelrys Inc.: San Diego, CA.
64. Rogers, D.; Hahn, M. Extended-connectivity fingerprints J. Chem. Inf. Model. 2010, 50, 742-754